Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Short Interest Update

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) saw a significant growth in short interest in November. As of November 30th, there was short interest totalling 386,500 shares, a growth of 22.7% from the November 15th total of 315,000 shares. Based on an average daily trading volume, of 3,150,000 shares, the short-interest ratio is presently 0.1 days. Approximately 5.1% of the shares of the stock are sold short.

Hedge Funds Weigh In On Virpax Pharmaceuticals

A hedge fund recently bought a new stake in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC acquired a new position in shares of Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned 1.17% of Virpax Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 32.23% of the company’s stock.

Virpax Pharmaceuticals Stock Up 32.9 %

VRPX stock opened at $0.40 on Friday. The company has a fifty day moving average price of $0.56 and a 200-day moving average price of $0.77. Virpax Pharmaceuticals has a 52-week low of $0.29 and a 52-week high of $5.48.

Analyst Ratings Changes

Separately, Maxim Group reaffirmed a “hold” rating on shares of Virpax Pharmaceuticals in a research note on Wednesday, October 9th.

About Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.